Abstract A73: A Phase I first-in-human (FIH) study of SAR566658, an anti CA6-antibody drug conjugate (ADC), in patients (Pts) with CA6-positive advanced solid tumors (STs) (NCT01156870).
Keyword(s):
Phase I
◽
2018 ◽
Vol 36
(15_suppl)
◽
pp. 5565-5565
◽